Demystifying Psychedelic Treatments in Psychiatry: Is Ego Dissolution the Solution?
Michael Avissar, A. J. Ambrose
Psychiatric News April 1, 2022 DOI: 10.1176/appi.pn.2022.04.4.35 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | News report Peer reviewed |
|---|---|
| Topics | Ego dissolution |
| Key points | Reports that interest in psychedelics is growing in clinical and research communities, as reflected in sessions at the APA Annual Meeting. It states that a growing body of research suggests psychedelic compounds may be useful for treating certain disorders, and describes classic psychedelics as those whose effects are primarily mediated by the serotonin 5HT2A receptor. |
Abstract
A growing body of research suggests that psychedelic compounds may be useful for treating patients with certain disorders. As highlighted by several sessions at the APA Annual meeting, there’s a growing renewed interest in psychedelics, which are compounds that induce changes in thought, perception, and mood, in the clinical and research communities. Classic psychedelics refer to a subset whose mind-manifesting and hallucinogenic effects are primarily mediated by the serotonin receptor, 5HT2A: tryptamines (for example, LSD, psilocybin, DMT, and 5-MeO-DMT), and phenethylamines (for example, MDMA and mescaline).